ArticleEndocrine2019
Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Characteristics and risk factors of cervical lymph node metastasis in cN0 papillary thyroid microcarcinoma of the isthmus.Updates in surgery · 2024Article
- Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases.Endocrine pathology · 2024Article
- TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases.Thyroid research · 2024Article
- Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Clinicopathological Features and Molecular Signatures of Lateral Neck Lymph Node Metastasis in Papillary Thyroid Microcarcinoma.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Younger Than 55 Years Old andInternational journal of general medicine · 2023Article
- Male patients with papillary thyroid cancer have a higher risk of extranodal extension.International journal of clinical oncology · 2022Article
- Article
- Whole-Exome Sequencing in Papillary Microcarcinoma: Potential Early Biomarkers of Lateral Lymph Node Metastasis.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Article
- The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.Journal of experimental & clinical cancer research : CR · 2020Article
- Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2020Review
- Characterization of thyroid cancer driven by known and novel ALK fusions.Endocrine-related cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
purposePapillary thyroid microcarcinoma (PTMC) has excellent outcomes, but extensive lymph node (LN) metastasis can be associated with fatal outcomes. We evaluated the mutational profiles of primary tumors and their metastatic LNs of PTMCs with extensive lateral cervical LN metastases.
methodsFormalin-fixed, paraffin-embedded archival samples from 16 sets of normal thyroid tissue, the primary PTMC, and the largest metastatic LN were used for targeted sequencing.
resultsA total of seven somatic variants were confirmed in the PTMCs compared to the normal tissue. The BRAF
conclusionThe mutational frequency of PTMCs was really low, even in those with extensive LN metastasis. The mutational status of the primary tumor and its metastatic LNs were not significantly different, and this suggests a minor role for genetic alterations in the process of LN metastasis in PTMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.